Effects of Continuous Anterior Chest Compression

Overview

The aim is to test the physiological effects of continuous anterior chest compression in patients with severe to moderate ARDS.

Full Title of Study: “” Effects of Continuous Anterior Chest Compression (CACC) & Comparision With Prone Position in ARDS Patients ” The StrapVent Study “”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 1, 2024

Detailed Description

Acute respiratory distress syndrome (ARDS) is usually characterized by inhomogeneous lesions, leading to an inhomogeneous distribution of the mechanical ventilation with the following several deleterious effects: atelectrauma of dependent posterior areas and overdistension in the anterior ones. Therefore, the gold standard treatment is to prevent VILI with lung protective ventilation : low tidal volume, high positive end expiratory pressure and prone positioning which is a technique that reduces mortality. Prone positioning has several beneficial effects : it relieves cardiac compression of the supporting lung, it stiffens the anterior chest wall thus limiting the risk of overdistension of anterior areas and promotes recruitment of non-dependent posterior pulmonary units. The overall effect is a more uniform distribution of transpulmonary pressures and improved ventilation to perfusion ratios. Similar to prone positioning, continuous anterior chest wall compression stiffens the anterior chest wall. The investigators hypothesize that such reduction in anterior chest wall compliance may protect against overdistension and promote the redistribution of the ventilation in posterior areas.

Interventions

  • Device: Continuous anterior chest compression
    • Patients with severe to moderate ARDS who were placed in prone position by the attending physician : First CACC : the applied pressure is equal to the one observed in the prone position Second CACC : The applied pressure is set at 60 – 80 cmH20

Arms, Groups and Cohorts

  • Experimental: A description of each arm of the clinical trial that indicates its role in the clinical trial
    • Arm 1 Description: The study will consitent of recording the measurments of ventilatory settings, respiratory mechanics, flow and pressure curves, gaz exchange, haemodynamics and ventilation distribution in 5 consecutive conditions in adult patients with moderate to severe ARDS : After 16 hours of prone position In supine position 1 hour after the prone position 15mn after CACC with a pressure equal to the one observed in the prone position 15mn after CACC with a pressure set at 60 – 80 cmH20 15mn after taking of the CACC

Clinical Trial Outcome Measures

Primary Measures

  • The end inspiratory transpulmonary pressure (PL-insp) in centimetre of water
    • Time Frame: Through study completion (up to 6 hours)
    • The transpulmonary pressure will be measured by using an esophageal catheter connected to a differential pressure transducer. The PL-insp will be calculated using the ratio between the elastance of the lung (El) and of the respiratory system (Ers) expressed in centimetre of water thanks to this formula PL-insp = Plateau pressure x (El/Ers). The PL-insp between the different protocol conditions will be compared (After 16 hours of prone position, in supine position, 15mn after CACC with a pressure equal to the one observed in the prone position, 15mn after CACC with a pressure set at 60 – 80 cmH20, 15mn after taking off the CACC in supine position ). CACC will be considered protective if there is a decrease in Pl-insp.

Secondary Measures

  • Regional pulmonary compliances in centimetre of water
    • Time Frame: Through study completion (up to 6 hours)
    • Evaluation and comparison of pulmonary compliances in the different regions of interest (ROI) measured by Electrical Impedance Tomography (EIT) in the different protocol conditions.
  • Lung mechanics : Airways pressure, Flow curves and Esophageal pressure
    • Time Frame: Through study completion (up to 6 hours)
    • Airways pressure (Paw) will be measured in cmH2O and recorded by the mean of a differential pressure transducer. Flow curves will be measured in L/mn and recorded by the mean of a pneumotachograph connected to the ventilator circuit. Esophageal pressure (Pes) will be measured in cmH2O and recorded thanks to an esophageal balloon catheter introduced in the mid-esophagus of the patient and connected to differential pressure transducer. Evaluation and comparison of respiratory mechanics in the different protocol conditions.
  • Pulmonary ventilation distribution in percentage
    • Time Frame: Through study completion (up to 6 hours)
    • Evaluation and comparison of the distribution of ventilation in the different regions of interest (ROI) measured by Electrical Impedance Tomography (EIT) in the different protocol conditions
  • Recruitment-to-inflation (R/I) ratio
    • Time Frame: Through study completion (up to 6 hours)
    • Evaluation and comparaison of R/I in the different protocol conditions
  • Hemodynamics
    • Time Frame: Through study completion (up to 6 hours)
    • Heart rate will be expressed in beats per minute, arterial blood pressure will be expressed in millimetre of mercury and norepinephrine perfusion will be expressed in milligrams per hour.
  • Arterial blood gazes (ABG
    • Time Frame: Through study completion (up to 6 hours)
    • pH, PaCO2 and PaO2 will be measured by standard clinical technique using the ICU blood gaz analyzer. PaCO2 and PaO2 will be expressed in millimetre of mercury.
  • Incidence of CACC adverse events
    • Time Frame: Through study completion (up to 6 hours)
    • CACC will be interrupted if : Reduction in oxygen saturation (SpO2) beneath 88% despite FiO2 optimisation. Reduction in mean arterial pressure beneath 60 mmHg Increase in norepinephrine perfusion beyond 0.5 mg/h
  • End expiratory lung impedance (EELZ) expressed in arbitrary units
    • Time Frame: Through study completion (up to 6 hours) ]
    • Evaluation and comparison of EELZ using EIT in the different protocol conditions.

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 ans – Intubated moderate and severe ARDS according to the Berlin definition (PaO2/FiO2 ratio <= 200 mmHg) – The patent must be sedated and paralyzed – Informed consent from patient or family members Exclusion Criteria:

  • Extracorporeal membrane oxygenation (ECMO) – Pneumothorax – Thoracic trauma during the last 3 months – Refractory shock – Contraindication to EIT monitoring (e.g. burns, pacemaker, thoracic wounds limiting electrode belt placement) – Pregnancy – Any contra-indication to esophageal manometry (less than one month esophagus surgery, bronchopleural or esotracheal fistula, latex allergy) – No social care – Adults under Guardianship, curatorship or protection of the court

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Guillaume CARTEAUX, MD, PhD, Principal Investigator, APHP
  • Overall Contact(s)
    • Guillaume CARTEAUX, MD, PhD, (+33) 01 45 17 86 38, guillaume.carteaux@aphp.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.